Management of sickle cell disease: Recommendations from the 2014 expert panel report

American Family Physician

Volumn 92, Issue 12, 2015, Pages 1069-1076

  Yawn, Barbara P ^a,c   John Sowah, Joylene ^b  

^a OLMSTED MEDICAL CENTER   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; HEMOGLOBIN; HYDROMORPHONE; HYDROXYUREA; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE;

ACUTE CHEST SYNDROME; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; COMMUNITY CARE; CONSULTATION; DOPPLER ECHOGRAPHY; GENERAL PRACTITIONER; HEPATOBILIARY DISEASE; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; OXYGEN THERAPY; PAIN; PATIENT CARE; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIAPISM; QUALITY OF LIFE; RETINOPATHY; SICKLE CELL ANEMIA; SPIROMETRY; VACCINATION; VASCULAR DISEASE; VASOOCCLUSIVE CRISIS; ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; CHILD; FEMALE; GENERAL PRACTICE; INFANT; MALE; MEDICAL EDUCATION; MIDDLE AGED; PATIENT EDUCATION; PRESCHOOL CHILD; STANDARDS; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; EDUCATION, MEDICAL, CONTINUING; FAMILY PRACTICE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; YOUNG ADULT;

EID: 84949764099     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert panel report, 2014. http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report.pdf. Accessed September 29, 2015.
2. Connes P, Lamarre Y, Waltz X, et al. Haemolysis and abnormal haemorheology in sickle cell anaemia. Br J Haematol. 2014;165(4):564-572.
3. Ballas SK, Mohandas N. Sickle red cell microrheology and sickle blood rheology. Microcirculation. 2004;11(2):209-225.
4. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762-769.
5. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938.
6. Haywood C Jr, Beach MC, Lanzkron S, et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc. 2009;101(10):1022-1033.
7. Miller ST, Wright E, Abboud M, et al.; STOP Investigators. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785-789.
8. Raphael JL, Oyeku SO, Kowalkowski MA, Mueller BU, Ellison AM. Trends in blood transfusion among hospitalized children with sickle cell disease. Pediatr Blood Cancer. 2013;60(11):1753-1758.
9. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986; 314(25):1593-1599.
10. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr. 1995;127(5):685-690.
11. Nkouwap I, Diara JP, Noyon I, Étienne-Julan M, Mérault L. Is there any alternative to oral penicillin in antibioprophylaxis for children with sickle cell disease? [French] Med Mal Infect. 1999;29(2):111-116.
12. Hussain S, Nichols F, Bowman L, Xu H, Neunert C. Implementation of transcranial Doppler ultrasonography screening and primary stroke prevention in urban and rural sickle cell disease populations [published online ahead of print November 8, 2104]. Pediatr Blood Cancer. http://onlinelibrary.wiley.com/doi/10.1002/pbc.25306/abstract;jsessionid=29B91A94C6C6DF5DD715B5C97694E336.f01t04. Accessed September 22, 2015.
13. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 2001;103(1):163-182.
14. Enninful-Eghan H, Moore RH, Ichord R, Smith-Whitley K, Kwiatkowski JL. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J Pediatr. 2010;157(3):479-484.
15. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
16. Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778.
17. Smith-Whitley K. Reproductive issues in sickle cell disease. Blood. 2014;124(24):3538-3543.
18. Barfield WD, Barradas DT, Manning SE, Kotelchuck M, Shapiro- Mendoza CK. Sickle cell disease and pregnancy outcomes: women of African descent. Am J Prev Med. 2010;38(4 suppl):S542-S549.
19. Alayed N, Kezouh A, Oddy L, Abenhaim HA. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med. 2014;42(4):487-492.
20. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
21. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
22. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647-3656.
23. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997;350(9088):1358-1361.
24. Hagmeyer KO, Mauro LS, Mauro VF. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother. 1993;27(1):29-32.
25. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published corrections appear in JAMA. 2014;312(18):1932, and JAMA. 2015;313(7):729]. JAMA. 2014;312(10):1033-1048.
26. Vichinsky EP, Neumayr LD, Earles AN, et al.; National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease [published correction appears in N Engl J Med. 2000;343(11):824]. N Engl J Med. 2000;342(25):1855-1865.
27. Abbas HA, Kahale M, Hosn MA, Inati A. A review of acute chest syndrome in pediatric sickle cell disease. Pediatr Ann. 2013;42(3):115-120.
28. Ahmad FA, Macias CG, Allen JY. The use of incentive spirometry in pediatric patients with sickle cell disease to reduce the incidence of acute chest syndrome. J Pediatr Hematol Oncol. 2011;33(6):415-420.
29. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14(1):e2-e12.
30. Charache S, Terrin ML, Moore RD, et al.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995; 332(20):1317-1322.
31. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990;322(15):1037-1045.
32. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656.
33. Wang WC, Ware RE, Miller ST, et al.; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778): 1663-1672.
34. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139(6):790-796.
35. Kinney TR, Helms RW, O’Branski EE, et al.; Pediatric Hydroxyurea Group. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood. 1999;94(5):1550-1554.
36. Steinberg MH, McCarthy WF, Castro O, et al.; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients’ Follow-Up. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6): 403-408.
37. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2013;(2013):439-446.
38. Smith-Whitley K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer. 2012;59(2):358-364.